As expected, BRCA1/2 variants comprised the majority of the tumor/germline variants in patients with stage III/IV breast, ovarian and pancreatic cancers; however, we also detected tumor/germline BRCA2 variants in atypical cancers such as colorectal, esophagogastric, NSCLC, and sarcoma. This evidence concerns the gene BRCA2 and pancreatic neoplasm.